Articles Related to Glioblastoma Multiforme
Successful use of Eltrombopag for Management of Temozolomide Related Severe Prolonged Thrombocytopenia and Aplastic Anaemia in The Treatment of Glioblastoma Multiforme (GBM) in a Regional Centre: A Case Report and Literature Review
Temozolomide is an orally administered chemotherapeutic drug used concurrently with radiation for the treatment of newly diagnosed glioblastoma. Although the addition of Temozolomide has shown to improve overall survival, it is commonly associated with haematological complications. Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that is also used off-label for temozolomide-induced aplastic anaemia.
Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.